Drought Breaker: New GA Treatments to Impact Optometry
Provider: Mivision
Contact: Nikki Byrne, [E] nikki@mivision.com.au, [P] 02 8336 8616
Activity Outline
One of the defining moments in ophthalmology was the
introduction of intravitreal anti-VEGFs to treat neovascular age-related
macular degeneration (nAMD). Now, eye care professionals outside the United
States await news from their respective regulatory bodies about the approval of
the newest intravitreal injection (IVI) agents, pegcetacoplan and avacincaptad
pegol. Given the green light by the United States Food and Drug Administration
(FDA) last year, these drugs represent the first-ever treatments for geographic
atrophy (GA) – and the first real hope for clinicians and patients alike.
So, what would a post-approval patient pathway look like, and how can we manage their expectations?
Learning Objectives
- Be aware of the GA treatment options awaiting TGA approval
- Understand the pathology, symptoms, and functional impact of GA
- Be able to identify GA using OCT
- Describe an ideal management pathway for patients with GA
- Realise the role of optometry in screening, referring on, counselling, and maintaining communication between patients with GA and retinal specialists
Max CPD hours awarded: 1.25
Session Information
| Name |
|---|
| Drought Breaker: New GA Treatments to Impact Optometry |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.75 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.25 |